TrivarX Limited (AU:TRI) has released an update.
TrivarX Limited is nearing completion of its Phase 2 SAMDE study, having enrolled 362 patients to evaluate its AI-powered algorithm, MEB-001, for diagnosing major depressive episodes. The company anticipates the trial’s results will support further discussions with the FDA, and has bolstered its commercial strategy by appointing healthcare veteran W. Drew Palin as a strategic advisor. Additionally, TrivarX showcased its technology at the SLEEP 2024 conference, leading to several follow-up engagements.
For further insights into AU:TRI stock, check out TipRanks’ Stock Analysis page.
